FCRL4 and peeling skin syndrome: Thus, B-cell targeting therapies, such as rituximab, that deplete FcRL4+ B cells and restore of the ductal epithelium may be beneficial in patients with pSS and even prevent MALT lymphoma development within the salivary glands.